Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma | Journal of Experimental & Clinical Cancer Research | Full Text

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma | Journal of Experimental & Clinical Cancer Research | Full Text

• 
• Owned by the Association for International Promotion & Study in Tumors (APSIT)
• 
• Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as th...

Authors:Ninadh M. D’Costa, Matthew R. Lowerison, Peter A. Raven, Zheng Tan, Morgan E. Roberts, Raunak Shrestha, Matthew W. Urban, Cesar U. Monjaras-Avila, Htoo Zarni Oo, Antonio Hurtado-Coll, Claudia Chavez-Munoz and Alan I. So

Citation:Journal of Experimental & Clinical Cancer Research 2020 39:33

Content type:Research

Published on: 10 February 2020

• ViewFull Text
 
• ViewPDF